Publications by authors named "Martin Slater"

Claim this Profile
A
A non-canonical AKT1-TERT pathway coordinates autophagy and ERphagy.
Vishnu Suresh Babu, Sayan Ghosh, Sridhar Bammidi, Ryu Jiwon, Ruchi Sharma, Martin J Slater

bioRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Methods for Ranking Ligand-Protein Interactions and Predicting Binding Affinities: Which Method is Right for You?
Stuart Lang, Natércia F Braz, Martin J Slater, Nathan J Kidley

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Free Energy Perturbation (FEP) Methodology for Predicting the Binding Affinity of Macrocyclic JAK2 Inhibitor Analogues of Pacritinib.
Natércia F Braz, Martin J Slater, Stuart Lang

ACS Med Chem Lett· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.
Guillaume Dutheuil, Killian Oukoloff, Julien Korac, François Lenoir, Mohamed El Bousmaqui, Martin J Slater

J Med Chem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virtual Screening Strategies for Identifying Novel Chemotypes.
Stuart Lang, Martin J Slater

J Med Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined and Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells.
Saiful Islam, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H Martin

Pharmaceuticals (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of neomycin analogues for HIV-1 RRE RNA recognition identifies enhanced activity simplified neamine analogues.
Binto Simon, Claire Walmsley, Victoria J Jackson, Edward P Garvey, Martin J Slater

Bioorg Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.
Jason D Oliver, Graham E M Sibley, Nicola Beckmann, Katharine S Dobb, Martin J Slater

Proc Natl Acad Sci U S A· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thematic Analysis™: a chemogenomic approach to GPCR drug discovery.
Roger Crossley, Jacqueline Anne Macritchie, Martin John Slater

Curr Top Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design and application of target-focused compound libraries.
C John Harris, Richard D Hill, David W Sheppard, Martin J Slater, Pieter F W Stouten

Comb Chem High Throughput Screen· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
Xianfeng Li, Yong-Kang Zhang, Yang Liu, Charles Z Ding, Yasheen Zhou, Martin J Slater

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of novel alpha-amino cyclic boronates as inhibitors of HCV NS3 protease.
Xianfeng Li, Yong-Kang Zhang, Yang Liu, Charles Z Ding, Qun Li, Martin J Slater

Bioorg Med Chem Lett· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unexpected stereochemical course of dihydroimidazolium ylide cycloadditions.
Raymond C F Jones, Shabana Rafiq, Mark R J Elsegood, Vickie McKee, Martin J Slater

Chem Asian J· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymmetric synthesis of an N-acylpyrrolidine for inhibition of HCV polymerase.
Armel A Agbodjan, Bob E Cooley, Royston C B Copley, John A Corfield, Roy C Flanagan, Martin J Slater

J Org Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity.
George Burton, Thomas W Ku, Thomas J Carr, Terry Kiesow, Robert T Sarisky, Martin J Slater

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
Martin J Slater, Elizabeth M Amphlett, David M Andrews, Gianpaolo Bravi, George Burton

J Med Chem· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The regiospecific one-pot phosphorylation of either the 5'- or 2'-hydroxyl in 3'-deoxycytidines without protection: critical role of the base.
Peter D Howes, Martin J Slater, Katrina Wareing

Nucleosides Nucleotides Nucleic Acids· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
Martin J Slater, Elizabeth M Amphlett, David M Andrews, Paul Bamborough, Seb J Carey

Org Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease.
David M Andrews, Michael C Barnes, Mike D Dowle, S Lucy Hind, Martin R Johnson, Martin J Slater

Org Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of spiro-cyclopentenyl and spiro-[1,3]-dithiolanyl substituted pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
David M Andrews, Paul S Jones, Gail Mills, S Lucy Hind, Martin J Slater

Bioorg Med Chem Lett· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design of potent, non-peptidic inhibitors of hepatitis C protease.
David M Andrews, Helene M Chaignot, Barry A Coomber, Mike D Dowle, S Lucy Hind, Martin J Slater

Eur J Med Chem· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators.
Markus Thor, Katarina Beierlein, Graeme Dykes, Anna Lena Gustavsson, Jessica Heidrich, Martin Slater

Bioorg Med Chem Lett· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
David M Andrews, Seb J Carey, Helene Chaignot, Barry A Coomber, Norman M Gray, Martin J Slater

Org Lett· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents.
David M Andrews, Helene Chaignot, Barry A Coomber, Andrew C Good, S Lucy Hind, Martin J Slater

Org Lett· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of potential anti-HIV GP120 inhibitors using a lysine template.
Valerie E Doyl, Thomas Klimkait, Naheed Mahmood, Martin Slater, Richard J Hazen

J Enzyme Inhib Med Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis